Community Position Statement: DRV/r Must Urgently Become the Preferred Protease Inhibitor Used in Adult Second-Line ART

Please read the full statement here:

Darunavir/ritonavir (DRV/r) is a highly effective and well-tolerated protease inhibitor that has been used to treat people living with HIV (PLHIV) for over a decade. Though DRV/r has seen significant utilization in many high-income settings, this has not been the case in low- and middle-income countries (LMICs) despite DRV/r’s significant benefits. However, the recent development of a quality-assured FDC of DRV/r that is now available at a price below that of LPV/r paves the way for the uptake of DRV/r in LMICs to replace poorly tolerated medicines. We, as HIV community advocates representing over 40 organizations spanning 20 countries, demand that all global and national stakeholders rapidly adopt, procure, and introduce DRV/r so that those PLHIV that are poorly tolerating their medicines will finally have a path to a happier and healthier life

Published: December 3, 2021
Last edited: December 3, 2021